MX2022001022A - Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. - Google Patents

Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.

Info

Publication number
MX2022001022A
MX2022001022A MX2022001022A MX2022001022A MX2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A MX 2022001022 A MX2022001022 A MX 2022001022A
Authority
MX
Mexico
Prior art keywords
bispecific antibody
her2
cancer
treating
preventing
Prior art date
Application number
MX2022001022A
Other languages
English (en)
Inventor
Na Rae Lee
Taewang Kim
Moo Young Song
Seawon Ahn
Donghoon Yeom
Young Bong Park
Eunyoung Park
Yangsoon Lee
Hyejin Chung
Eunjung Kim
Yong-Gyu Son
Yeryoung Yong
Ui-Jung Jung
Kyeongsu Park
Wonjun Son
Eun-Jung Lee
Eun Jung Lee
Chanmoo Lee
Junghyeon Hong
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2022001022A publication Critical patent/MX2022001022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan un anticuerpo biespecífico anti-41BB/anti-HER2 y una composición farmacéutica y un método para tratar y/o prevenir un cáncer usando la misma.
MX2022001022A 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. MX2022001022A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878951P 2019-07-26 2019-07-26
US202063024608P 2020-05-14 2020-05-14
PCT/KR2020/009871 WO2021020846A1 (en) 2019-07-26 2020-07-27 Anti-her2/anti-4-1bb bispecific antibody and use thereof

Publications (1)

Publication Number Publication Date
MX2022001022A true MX2022001022A (es) 2022-04-18

Family

ID=74190718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001022A MX2022001022A (es) 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.

Country Status (10)

Country Link
US (1) US20210024650A1 (es)
EP (1) EP4004054A4 (es)
JP (1) JP2022542574A (es)
KR (1) KR20220038768A (es)
AU (1) AU2020320233A1 (es)
BR (1) BR112022001336A8 (es)
CA (1) CA3147423A1 (es)
MX (1) MX2022001022A (es)
WO (1) WO2021020846A1 (es)
ZA (1) ZA202200906B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021228078A1 (en) * 2020-02-28 2022-09-22 Shanghai Henlius Biotech, Inc. Anti-CD137 constructs, multispecific antibody and uses thereof
WO2022029496A1 (en) * 2020-08-07 2022-02-10 Eutilex Co., Ltd. Anti-her2 / anti-4-1bb bispecific antibodies and uses thereof
WO2023195810A1 (en) * 2022-04-07 2023-10-12 Yuhan Corporation Pharmaceutical composition for treating or preventing cancer with low expression level of her2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3019531A1 (en) * 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
RU2727165C2 (ru) * 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
CN108064246A (zh) * 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
KR20220163523A (ko) * 2016-03-31 2022-12-09 바이오엔테크 유에스 인크. 신생항원 및 이것의 사용 방법
CA3021618A1 (en) * 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
CN110139669A (zh) * 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
KR102585848B1 (ko) * 2017-02-24 2023-10-11 마크로제닉스, 인크. Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
WO2019016402A1 (en) * 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途

Also Published As

Publication number Publication date
ZA202200906B (en) 2023-11-29
US20210024650A1 (en) 2021-01-28
BR112022001336A2 (pt) 2022-03-22
EP4004054A4 (en) 2023-10-25
JP2022542574A (ja) 2022-10-05
BR112022001336A8 (pt) 2023-02-07
CN114206941A (zh) 2022-03-18
AU2020320233A8 (en) 2022-02-24
CA3147423A1 (en) 2021-02-04
EP4004054A1 (en) 2022-06-01
KR20220038768A (ko) 2022-03-29
AU2020320233A1 (en) 2022-02-17
WO2021020846A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
WO2020082209A8 (zh) 抗cldn18.2抗体及其用途
EP4039707A4 (en) CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF
EP3853257A4 (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
EP3752180A4 (en) METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
AU2019206958A1 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
IL286504A (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for tumor treatment
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2020003395A (es) Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
EP4076482A4 (en) COMPOSITIONS FOR MODULATING INTESTINAL MICROFLORA POPULATIONS, IMPROVING THE EFFECTIVENESS OF DRUGS AND TREATING CANCER, AND METHODS FOR THE PRODUCTION AND USE OF THE SAME
EP3909981A4 (en) HUMANIZED ANTI-BETA-1 INTEGRIN ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER THEREOF
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.